$-0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)

March 14, 2018 - By Michael Collier

 $ 0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)
Investors sentiment increased to 1.32 in Q3 2017. Its up 0.23, from 1.09 in 2017Q2. It is positive, as 10 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported.
45,040 are held by Victory Cap Mgmt. Point72 Asset Management L P holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 300,300 shares. Jane Street Group Lc owns 14,007 shares. Evercore Wealth Mngmt Limited Liability Co reported 168,414 shares. The New York-based 683 Management Limited Com has invested 0.96% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Vanguard Grp holds 4.26 million shares. Excalibur Mngmt stated it has 0.03% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Eam Ltd Liability Company holds 0.38% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 785,338 shares. Essex Invest Limited Company owns 150,620 shares. Citigroup holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2,670 shares. Blackrock holds 1.88 million shares. Cubist Systematic Strategies Limited reported 11,325 shares. Gsa Cap Prns Ltd Liability Partnership stated it has 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Prelude Capital, New York-based fund reported 87,709 shares. Sphera Funds Mgmt Ltd holds 0.73% or 1.40M shares in its portfolio.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.02 EPS on March, 28.They anticipate $0.09 EPS change or 81.82 % from last quarter’s $-0.11 EPS. After having $-0.02 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.73% or $0.08 during the last trading session, reaching $2.85. About 1.30M shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 16.67% since March 15, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals had 13 analyst reports since March 30, 2016 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, August 9 report. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Outperform” rating by FBR Capital on Wednesday, March 30. The firm has “Buy” rating by FBR Capital given on Tuesday, January 16. The stock has “Buy” rating by FBR Capital on Monday, February 12. FBR Capital maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Monday, June 26 with “Buy” rating. Piper Jaffray maintained it with “Buy” rating and $5.0 target in Thursday, October 5 report. As per Monday, August 28, the company rating was upgraded by Piper Jaffray. FBR Capital maintained the stock with “Buy” rating in Thursday, December 7 report. The firm has “Buy” rating by FBR Capital given on Tuesday, March 13. On Thursday, May 19 the stock rating was initiated by Piper Jaffray with “Overweight”.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $437.79 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Another recent and important AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news was published by Zacks.com which published an article titled: “AVEO Pharmaceuticals’ (AVEO) Q4 Earnings: What’s in Store?” on March 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.